Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance.

Mariottini, Alice; Repice, Anna Maria; Barilaro, Alessandro; Massacesi, Luca

Mariottini, Alice; Repice, Anna Maria; Barilaro, Alessandro; Massacesi, Luca.

Mariottini A; Department of Neurosciences, Drug and Child Health, University of Florence, Viale Gaetano Pieraccini, 6, 50139, Florence, FI, Italy.
Repice AM; Tuscany Region Multiple Sclerosis Referral Centre, Neurology 2, University Hospital of Careggi, Florence, Italy.
Barilaro A; Tuscany Region Multiple Sclerosis Referral Centre, Neurology 2, University Hospital of Careggi, Florence, Italy.
Massacesi L; Tuscany Region Multiple Sclerosis Referral Centre, Neurology 2, University Hospital of Careggi, Florence, Italy.

Neurol Sci ; 43(7): 4095-4097, 2022 07.

Article in English | MEDLINE | ID: covidwho-1756821

Subject(s)

COVID-19; COVID-19/prevention & control; Humans; Pandemics/prevention & control; Product Surveillance, Postmarketing; Vaccination/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: S10072-022-05961-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google